UPDATE: Cantor Fitzgerald Starts PolyPid Ltd. (PYPD) at Overweight

July 30, 2021 6:13 AM EDT
Get Alerts PYPD Hot Sheet
Price: $8.04 -2.31%

Rating Summary:
    6 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 5 | New: 36
Trade Now! 
Join SI Premium – FREE
(Updated - July 30, 2021 6:14 AM EDT)

Cantor Fitzgerald analyst Brandon Folke initiates coverage on PolyPid Ltd. (NASDAQ: PYPD) with a Overweight rating and a price target of $24.00.

The analyst comments "Polypid is developing D-PLEX100 for the management of Surgical Site infections (SSIs) in bone and soft tissue. PYPD expects to readout data from its single Phase 3 required for NDA filing by year-end 2021. Beyond the potential initial approval in the management of SSIs in colorectal surgery, we expect PYPD to pursue label expansion for D-PLEX100 and leverage the PLEX technology platform to address other large unmet needs outside of SSIs. We expect data readouts and product approvals to potentially drive upside to the stock."

For an analyst ratings summary and ratings history on PolyPid Ltd. click here. For more ratings news on PolyPid Ltd. click here.

Shares of PolyPid Ltd. closed at $7.23 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage

Related Entities

Cantor Fitzgerald